Group 1 - The company plans to raise up to 185 million yuan through a simplified procedure for issuing A-shares, with funds allocated for acquiring a 22.2324% stake in Nanda Pharmaceutical and supplementing working capital [1] - The acquisition will increase the company's direct stake in Nanda Pharmaceutical to 73.358%, which is expected to enhance the company's performance and support its integrated strategy of "raw materials + formulations" [2] - Nanda Pharmaceutical is one of the few companies in China with both raw material and formulation approvals for urokinase, which will help the company extend its human protein product business into downstream finished formulations [2] Group 2 - The company showcased its third-generation integrase product ACC017 at the J.P. Morgan conference, highlighting its core technological advantages and product first-mover advantages in the anti-HIV field [3] - The current pipeline includes two approved first-class new drugs and ongoing clinical trials for ACC017, which is in Phase III, along with other promising candidates in HIV prevention [3] - The company maintains a "buy" rating, with profit forecasts for 2025-2027 being 0.07 billion, 0.89 billion, and 1.66 billion yuan respectively, not accounting for the impact of the upcoming share issuance [3]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market [6]. Core Insights - The company plans to raise up to 185 million yuan through a simplified procedure for issuing A-shares, with funds allocated for acquiring a 22.2324% stake in Nanda Pharmaceutical and for supplementing working capital [6]. - The acquisition of Nanda Pharmaceutical is expected to enhance the company's integrated strategy of "raw materials + formulations," increasing its direct stake to 73.358% [6]. - The company has a robust pipeline of human-derived protein products, including new drugs AD010, AD108, and ADB116, with AD108 and ADB116 receiving clinical approval in 2025 [6]. - The company showcased its third-generation integrase product ACC017 at the J.P. Morgan conference, highlighting its competitive edge in the HIV treatment market [6]. Financial Data and Profit Forecast - Total revenue is projected to grow from 418 million yuan in 2024 to 1.263 billion yuan in 2027, with a compound annual growth rate (CAGR) of approximately 26.7% [5]. - The net profit is expected to turn positive in 2025, reaching 7 million yuan, and further increasing to 166 million yuan by 2027, reflecting a significant growth trajectory [5]. - The gross margin is forecasted to improve from 54.9% in 2024 to 75.2% in 2027, indicating enhanced operational efficiency [5]. - The return on equity (ROE) is anticipated to rise from -14.4% in 2024 to 13.4% in 2027, suggesting a recovery in profitability [5].

Group 1 - Eddie Pharmaceutical's stock increased by 5.12%, reaching 17.86 CNY per share, with a trading volume of 74.09 million CNY and a turnover rate of 1.02%, resulting in a total market capitalization of 7.515 billion CNY [1] - The company, established on December 15, 2009, and listed on July 20, 2020, is located in Yangzhou, Jiangsu Province, and focuses on the exploration, research, and sales of innovative chemical drugs and human-derived protein products [1] - The revenue composition of Eddie Pharmaceutical includes human-derived proteins at 41.11%, new drugs at 35.69%, diagnostic equipment, reagents, and others at 13.62%, generic drugs at 9.47%, and other supplementary products at 0.11% [1] Group 2 - Among the top ten circulating shareholders of Eddie Pharmaceutical, a fund under Huatai-PineBridge holds 4.6607 million shares, accounting for 1.11% of the circulating shares, with an estimated floating profit of approximately 4.0548 million CNY [2] - The Huatai-PineBridge Medical Health Mixed Fund (470006) was established on September 21, 2010, with a latest scale of 2.486 billion CNY, achieving a year-to-date return of 10.43% and a one-year return of 41.9% [2] - The fund ranks 654 out of 8838 in year-to-date performance and 3211 out of 8089 in one-year performance, with a cumulative return of 171.57% since inception [2]

中国经济网北京1月14日讯 艾迪药业(688488.SH)昨晚披露了关于终止公司2024年度向特定对象发行 A股股票的公告和2026年度以简易程序向特定对象发行A股股票预案。 艾迪药业于2026年1月13日召开第三届董事会第十一次会议，审议通过了《关于终止公司2024年度 向特定对象发行A股股票事项的议案》等相关议案，公司决定终止2024年度向特定对象发行A股股票事 项，本事项无需提交公司股东会审议。 艾迪药业2024年8月12日召开第二届董事会第二十五次会议、第二届监事会第二十四次会议，审议 通过了《关于公司2024年度向特定对象发行A股股票方案的议案》等相关议案，同意公司拟向傅和亮发 行不超过14,534,883股（含本数）股份，募集资金总额不超过10,000.00万元（含本数），扣除相关发行 费用后的募集资金净额全部拟用于补充流动资金。傅和亮为公司实际控制人之一。傅和亮，男，中国国 籍，拥有加拿大居留权。 艾迪药业表示，自公司披露2024年度向特定对象发行A股股票事项以来，公司一直在积极推进各项 工作，并严格按照相关法律法规和规范性文件要求履行了决策程序和信息披露义务。 截至目前，公司拟开展2026年度 ...

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Insights - The company plans to raise up to 185 million yuan through a simplified procedure for issuing A-shares, with funds allocated for acquiring a 22.2324% stake in Nanda Pharmaceutical and for supplementing working capital [6] - The acquisition will increase the company's direct stake in Nanda Pharmaceutical to 73.358%, which is expected to enhance the company's performance as Nanda reported a net profit of 55.81 million yuan from January to October 2025 [6] - The company is advancing its human-derived protein product pipeline, including new drugs AD010, AD108, and ADB116, with AD108 receiving clinical approval in 2025 for treating acute ischemic stroke [6] - The company showcased its third-generation integrase product ACC017 at the J.P. Morgan conference, indicating its commitment to becoming a leading brand in HIV innovation while expanding into international markets [6] Financial Summary - Projected total revenue for 2025 is 806 million yuan, with a year-on-year growth rate of 92.8% [5] - Expected net profit for 2025 is 7 million yuan, with a significant increase projected to 89 million yuan in 2026 and 166 million yuan in 2027 [5] - The gross margin is expected to improve from 63.2% in 2025 to 75.2% in 2027 [5]

登录新浪财经APP 搜索【信披】查看更多考评等级 2020年6月30日，本公司与子公司南京安赛莱医药科技有限公司、广发银行股份有限公司扬州分行、中 国建设银行股份有限公司南京鼓楼支行和华泰联合证券签署《募集资金专户存储五方监管协议》,在广 发银行股份有限公司扬州分行开设募集资金专项账户(账号：9550880058239300203),在中国建设银行股 份有限公司南京鼓楼支行(建宁路支行)开设募集资金专项账户(账号：32050159524609999996)。 2020年6月30日，本公司与子公司扬州艾迪医药科技有限公司、江苏银行股份有限公司扬州分行和华泰 联合证券签署《募集资金专户存储四方监管协议》,在江苏银行股份有限公司扬州分行(唐城支行)开设募 集资金专项账户(账号：90160188000125327)。 2022年1月19日，公司召开第一届董事会第二十一次会议和第一届监事会第十七次会议，审议通过了 《关于变更部分募集资金专项账户及新增募集资金专项账户的议案》。 2022年1月26日，本公司与中国建设银行股份有限公司江苏省分行和华泰联合证券签署《募集资金专户 存储三方监管协议》,在中国建设银行股份有限公司 ...

Group 1: Shanghai Pudong Development Bank - The bank reported a net profit of 50.017 billion yuan for 2025, an increase of 10.52% year-on-year [1][2] - Total operating income reached 173.964 billion yuan, reflecting a growth of 1.88% compared to the previous year [2] - The bank's total assets exceeded 1 trillion yuan, reaching 1,008.1746 billion yuan, a 6.55% increase from the previous year [3] Group 2: Dongpeng Beverage - Dongpeng Beverage expects a net profit between 4.34 billion and 4.59 billion yuan for 2025, representing a year-on-year growth of 30.46% to 37.97% [4] - The anticipated operating income is projected to be between 20.76 billion and 21.12 billion yuan, indicating a growth of 31.07% to 33.34% [4] Group 3: TCL Technology - TCL Technology forecasts a net profit of 4.21 billion to 4.55 billion yuan for 2025, marking a significant increase of 169% to 191% year-on-year [5][6] - The company expects to surpass 100 billion yuan in operating revenue, with net profit exceeding 8 billion yuan [5] Group 4: Changjiang Electric Power - Changjiang Electric Power reported a net profit of 34.167 billion yuan for 2025, a 5.14% increase year-on-year [8] - The total operating revenue for the year is expected to be 85.882 billion yuan, reflecting a growth of 1.65% [8] Group 5: China Gold - China Gold anticipates a net profit of 286 million to 368 million yuan for 2025, a decrease of 55% to 65% year-on-year [21] - The decline is attributed to market fluctuations and reduced consumer traffic [21] Group 6: LaKala - LaKala expects a net profit between 1.06 billion and 1.2 billion yuan for 2025, representing a growth of 202% to 242% year-on-year [22] - The increase is primarily due to significant investment income from stock holdings [22] Group 7: Baiwei Storage - Baiwei Storage projects a net profit of 850 million to 1 billion yuan for 2025, indicating a year-on-year increase of 427% to 520% [23] - The growth is driven by improved sales and gross margins in the AI sector [23] Group 8: Shengxin Lithium Energy - Shengxin Lithium Energy forecasts a net loss of 600 million to 850 million yuan for 2025, similar to the previous year's loss [24] - The company attributes the loss to industry supply-demand dynamics and increased exchange losses [24] Group 9: Zhongguancun Online - Zhongguancun Online expects a net loss of 580 million to 700 million yuan for 2025, a significant increase from the previous year's loss of 243 million yuan [25] - The losses are linked to increased promotional investments in overseas markets [25] Group 10: Huaxia Happiness - Huaxia Happiness anticipates a net loss of 16 billion to 24 billion yuan for 2025, a substantial increase from the previous year's loss of 4.817 billion yuan [26] - The decline is due to reduced project turnover and high financial costs [26]

Core Viewpoint - The acquisition of an additional 22.2324% stake in Nanjing Nanda Pharmaceutical by Aidi Pharmaceutical strengthens its control and supports its integrated strategy in human-derived protein production and formulation [1][2]. Group 1: Acquisition Details - Aidi Pharmaceutical announced the acquisition of 22.2324% of Nanjing Nanda Pharmaceutical for 130.05954 million yuan, increasing its ownership from 51.1256% to 73.3580% [1]. - This acquisition is aimed at solidifying control and enhancing the implementation of the company's integrated strategy in human-derived protein [2]. Group 2: Strategic Benefits - The acquisition is expected to reinforce strategic management, enhance resource synergy, and improve operational efficiency by integrating production, channels, and platforms [2]. - The financial performance of Nanjing Nanda Pharmaceutical has shown steady growth, with revenues of 299 million yuan and net profits of 51.5177 million yuan in 2024, and 262 million yuan in revenue with net profits of 55.8111 million yuan from January to October 2025 [2]. Group 3: R&D Achievements - Following the previous acquisition, Aidi Pharmaceutical and Nanjing Nanda Pharmaceutical have successfully developed two human-derived protein drugs, AD108 and ADB116, which have received IND approval [3][4]. - These drugs are designed to meet clinical needs, with AD108 offering a subcutaneous delivery method and ADB116 providing a rapid intravenous administration option for acute ischemic stroke [4]. Group 4: Market Potential - The human-derived protein market, particularly for ischemic stroke treatment, is significant, with approximately 3.4 million new stroke cases annually in China, 80% of which are ischemic strokes [5]. - The market for ischemic stroke treatments is projected to grow, with a 2023 market size of approximately 12.9 billion yuan, indicating substantial opportunities for Aidi Pharmaceutical's new products [5]. Group 5: Future Outlook - Aidi Pharmaceutical plans to leverage this acquisition to deepen resource integration with Nanjing Nanda Pharmaceutical, accelerating the development of its human-derived protein pipeline [6]. - The company aims to capitalize on industry growth and enhance its position in the human-derived protein sector, contributing to high-quality development in the biopharmaceutical industry [6].

（文章来源：证券日报） 证券日报网讯 1月13日，艾迪药业发布公告称，公司基于总体工作安排，拟暂不召开股东会，后续将视 情况另行发布召开通知。 ...

Group 1: Company Announcements - Hongsheng Co., Ltd. has not generated revenue in the data center liquid cooling sector [1][2] - Oriental Pearl does not directly engage in AI business, and AI applications do not directly generate revenue [1][2] - Tongda Hai's AI-driven revenue accounts for a low proportion of the company's overall operating income [2] Group 2: Project Investments - Beibu Gulf Port plans to invest 11.403 billion yuan in the construction of a 300,000-ton terminal project in Fangcheng Port [1][2] - LeKai Film's subsidiary plans to invest 97.6675 million yuan in a TAC functional film coating production line project [2] Group 3: Contract Awards - Aopt has won a bid for a 120 million yuan 2D vision solution project for GoerTek in 2026 [1][2] - Anhui Expressway has won a project worth 7.237 billion yuan [2] Group 4: Equity Transfers - Aidi Pharmaceutical intends to acquire a 22.2324% stake in Nanda Pharmaceutical for 130 million yuan [1][2] Group 5: Share Buybacks - Kaifa Electric plans to repurchase shares worth between 30 million and 60 million yuan [1][2] - Haojiang Intelligent plans to repurchase shares worth between 1.5 million and 3 million yuan [3] - Huazhi Jie plans to invest 30 million to 50 million yuan in share repurchases [3] Group 6: Shareholding Changes - New Work Group, a shareholder of China New Group, plans to reduce its stake by no more than 3% [3] - Zhejiang Yongqiang's shareholder plans to reduce his stake by no more than 1.13% [3] - Xiangyu Medical's shareholder plans to reduce his stake by no more than 3% [3]